

CLAIMS

We claim:

1. A method of treating autoimmune disease comprising;
administering to a subject a with an autoimmune disease a therapeutically effective combination comprising interferon-beta and an interleukin-2 receptor antagonist.
2. The method of claim 1, wherein the therapeutically effective combination comprises a pharmaceutical composition comprising at least one interferon-beta and a pharmaceutical composition comprising at least one interleukin-2 receptor antagonist.
3. The method of claim 2, wherein the interferon-beta comprises interferon-beta 1a.
4. The method of claim 2, wherein the interferon-beta comprises interferon-beta 1b.
5. The method of claim 2, wherein the interferon-beta comprises a combination of interferon-beta 1a and interferon-beta 1b.
6. The method of claim 2, wherein the interleukin-2 receptor antagonist is anti-Tac.
7. The method of claim 2, wherein the autoimmune disease is multiple sclerosis.
8. The method of claim 7, wherein the interferon-beta is administered weekly, and wherein the interleukin-2 receptor antagonist is administered every other week for two weeks and then monthly.
9. The method of claim 8, wherein the interferon-beta is Betaseron and the interleukin-2 receptor antagonist is anti-Tac.
10. The method of claim 7, wherein the interferon-beta is administered every other day, and wherein the interleukin-2 receptor antagonist is administered every other week for two weeks and then monthly.
11. The method of claim 10, wherein the interferon-beta is Avonex or Rebif and the interleukin-2 receptor antagonist is anti-Tac.

12. The method of claim 7, wherein the interleukin-2 receptor antagonist is administered every other week.

13. The method of claim 7, wherein the multiple sclerosis is relapsing-remitting or secondary-progressive.

14. The method of claim 7, wherein the interferon-beta comprises interferon-beta 1a interferon-beta 1b, or combinations thereof and wherein the interleukin-2 receptor antagonist is anti-Tac.

15. The method of claim 14, wherein the interferon-beta 1a is Avonex or Rebif, the interferon-beta 1b is Betaseron, and the anti-Tac is daclizumab.

16. The method of claim 7, wherein the subject has been treated previously with interferon-beta alone and has failed to respond to treatment with interferon-beta alone.

17. The method of claim 15, wherein the daclizumab is administered at a dose of 1-2 mg/kg.

18. The method of claim 17, wherein the daclizumab is Zenapax.

19. The method of claim 2, wherein the interferon-beta is administered subcutaneously.

20. A method of treating multiple sclerosis comprising;
administering to a subject with multiple sclerosis who has been previously treated with interferon-beta alone and has failed to respond to treatment with interferon-beta alone, a therapeutically effective dose of anti-Tac.